摘要
目的分析硼替佐米辅助治疗多发性骨髓瘤患者的临床疗效及不良反应。方法 80例多发性骨髓瘤患者在接受化疗时,同时予以硼替佐米辅助治疗,每例患者至少治疗1个疗程,并进行疗效及安全性观察。结果 80例患者总有效率为86.25%,较好缓解率为63.75%,CR+n CR为56.25%。初治患者总有效率为91.81%,较好缓解率为75.41%,CR+n CR为68.85%;复治患者总反应率为68.42%,较好缓解率为26.32%,CR+n CR为15.79%,初治与复治总有效率、较好缓解率、CR+n CR等各项比较,P<0.01,差异有统计学意义,初治组优于复发难治组。生存分析显示,所有患者中位OS为128.5周(9~248周),中位PFS为110.5周(4~217周);各个分组的OS相比,差异均无统计学意义;初治组与复发难治组的PFS相比,差别有统计学意义。硼替佐米的不良反应主要有血液异常、胃肠道反应、末梢神经炎等。结论硼替佐米为基础的方案在初治和复发难治的MM患者当中均有较好的疗效,初治组患者的较好缓解率高于复发难治组患者,初治组比复发难治组的PFS长,主要不良反应有血液学异常、胃肠道反应、末梢神经炎,多数可以耐受。
Objective To analyze the clinical efficacy and adverse reactions of bortezomib adjuvant therapy for multiple myeloma. Methods 80 cases of multiple myeloma patients were given chemotherapy and multiple myeloma for at least 1 treatment course,the efficacy and safety were observed. Results The total efficacy of 80 cases was 86. 25%,the better response rate was 63. 75%,the CR + n CR was 56. 25%. While total efficacy of the first treatment group was 91. 81%,the better response rate was 75. 41% and the CR + n CR was 68. 85%,total efficacy of the recurrence group was 68. 42%,the better response rate was26. 32% and the CR + n CR was 15. 79%,The first treatment group were better than the recurrence group,there had significant difference( P < 0. 01). The median OS was 128. 5 weeks( 9 ~ 248 weeks),the median PFS was 110. 5 weeks( 4 ~ 217 weeks),the OS in the 2 groups had no significant difference,while the PFS between the first treatment group and the recurrence group had obvious difference. The adverse reactions of bortezomib were blood disorders,gastrointestinal reactions,peripheral neuritis,et al.Conclusion Bortezomib has great efficacy on both the first treatment and the recurrence patients,the first treatment group has higher remission rate than the recurrence group,the PFS of the first treatment group was longer than that of the recurrence group,the main adverse reactions are blood disorders,gastrointestinal reactions,peripheral neuritis,et al,and most are tolerable.
出处
《实用癌症杂志》
2015年第8期1261-1263,共3页
The Practical Journal of Cancer
